Journal: Health Expectations : An International Journal of Public Participation in Health Care and Health Policy

Article Title: What Are the Experiences, Views and Perceptions of Patients, Carers and Clinicians of Glucagon‐like Peptide‐1 Receptor Agonists (GLP‐1 RAs)? A Scoping Review

doi: 10.1111/hex.70251

Figure Lengend Snippet: Study characteristics of included studies.

Article Snippet: Ryden et al. [ ] , Brazil, Germany, Japan and the UK , Patients & HCPs , Experience of taking GLP‐1 RA (exenatide once weekly, liraglutide once daily) or clinical expert , Adults currently taking GLP‐1 RAs and began taking the medication more than 2 months before screening or currently on an oral diabetes medication and without experience with GLP‐1 RA treatment for T2DM. HCPs were experts in drug development or diabetes/endocrinology , 50 patients and 4 HCPs , Patients: 52.8 years, 46% HCPs: NR , NR , Y , AstraZeneca.

Techniques: Biomarker Discovery, Medications, Sampling

Journal: Health Expectations : An International Journal of Public Participation in Health Care and Health Policy

Article Title: What Are the Experiences, Views and Perceptions of Patients, Carers and Clinicians of Glucagon‐like Peptide‐1 Receptor Agonists (GLP‐1 RAs)? A Scoping Review

doi: 10.1111/hex.70251

Figure Lengend Snippet: Summary of findings of included studies.

Article Snippet: Ryden et al. [ ] , Brazil, Germany, Japan and the UK , Patients & HCPs , Experience of taking GLP‐1 RA (exenatide once weekly, liraglutide once daily) or clinical expert , Adults currently taking GLP‐1 RAs and began taking the medication more than 2 months before screening or currently on an oral diabetes medication and without experience with GLP‐1 RA treatment for T2DM. HCPs were experts in drug development or diabetes/endocrinology , 50 patients and 4 HCPs , Patients: 52.8 years, 46% HCPs: NR , NR , Y , AstraZeneca.

Techniques: Medications, Comparison, Injection, Control, Titration, Selection, Adjuvant, Clinical Proteomics, Drug discovery

Journal: JCI Insight

Article Title: Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial

doi: 10.1172/jci.insight.159863

Figure Lengend Snippet: Study diagram of patient flow according to CONSORT 2010 statement. Details regarding initial meetings and ineligibility for screening can be found in , and a flowchart for the 6-month follow-up can be found in . Of the 127 patients included in the study, 65 patients were randomized to 2 mg exenatide once weekly, and 62 patients were randomized to placebo. Thirty-two patients from the exenatide group and 26 patients from the placebo group completed the study after 26 weeks of trial participation. AUDIT, Alcohol Use Disorders Identification Test; CIWA-Ar, Clinical Institute Withdrawal Assessment for Alcohol, Revised.

Article Snippet: The funding sources and the manufacturer of exenatide once weekly (Bydureon, AstraZeneca) had no influence on the trial design or data analysis.

Techniques:

Journal: JCI Insight

Article Title: Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial

doi: 10.1172/jci.insight.159863

Figure Lengend Snippet: ( A ) Key fMRI findings showed reduced cue reactivity after 26 weeks of treatment with exenatide compared with placebo. Analysis revealed statistically significant interaction between the treatment and time on fMRI response in all 3 ROIs: ventral striatum [ F (1,31) = 4.744, P = 0.037, partial η 2 =0.133], dorsal striatum [ F (1,31) = 6.124, P = 0.019, partial η 2 = 0.165], putamen [ F (1,31) = 4.730, P = 0.037, partial η 2 = 0.132]. * P < 0.05. ( B ) In more detail, we found that at week 26, cue-induced activity was significantly lower in ventral striatum after treatment with exenatide compared with placebo ( M = –0.176, SE = 0.075, P = 0.025), but not in dorsal striatum ( M = –0.142, SE = 0.076, P = 0.073) nor in putamen ( M = –0.123, SE = 0.084, P = 0.153). At baseline, cue-induced activity did not differ significantly between groups. Within the exenatide group, cue-induced activity was significantly reduced from baseline to week 26 in ventral striatum ( M = –0.254, SE = 0.116, P = 0.044) and in dorsal striatum ( M = –0.351, SE = 0.156, P = 0.039), but not in putamen ( M = –0.405, SE = 0.202, P = 0.063). Within the placebo group, no statistically significant differences were found. ( A and B ) ROI data were analyzed using a repeated-measures ANOVA including factors group and time and an independent sample 2-tailed t test comparing groups (placebo and exenatide). Placebo, n = 16; exenatide, n = 17. Boxes represent upper and lower quartiles, the line represents the median, and the X represents the mean. Horizontal lines indicate significant interactions between treatment and time (* P < 0.05), and brackets indicate significant simple effects (* P < 0.05).

Article Snippet: The funding sources and the manufacturer of exenatide once weekly (Bydureon, AstraZeneca) had no influence on the trial design or data analysis.

Techniques: Activity Assay

Journal: JCI Insight

Article Title: Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial

doi: 10.1172/jci.insight.159863

Figure Lengend Snippet: Reduced cue-induced activation in the exenatide group compared with the placebo group after 26 weeks of treatment in the left caudate and septal area ( x , y , z coordinates = 0, 0, 4) ( A ) and right middle frontal gyrus ( x , y , z coordinates = 36, 20, 48) ( B ). A 2-sample 2-tailed t test was performed for the post hoc analyses to compare groups (placebo, exenatide) and within a group across time (placebo/exenatide: T1, T2). For the group comparisons, the contrast of interest used was ‘alcohol > neutral stimuli’, where the probability of a family wise error (FWE) was set to 0.05 to control for multiple statistical testing. Using the AlphaSim (3dClustSim) method, a combined voxel wise threshold of P < 0.001 and a cluster extent threshold of 101 voxels were calculated ( n = 22).

Article Snippet: The funding sources and the manufacturer of exenatide once weekly (Bydureon, AstraZeneca) had no influence on the trial design or data analysis.

Techniques: Activation Assay, Control

Journal: JCI Insight

Article Title: Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial

doi: 10.1172/jci.insight.159863

Figure Lengend Snippet: The exenatide group showed a reduction at follow-up in the response to the 2-back > 1-back task compared with the placebo group (2-way mixed-effect ANOVA; placebo, n = 16; exenatide, n = 17; control, n = 25) in 2 prefrontal clusters (frontal pole x , y , z = 34, 54, 20, corrected P < 0.002; superior frontal gyrus x , y , z = 4, 46, 46, corrected P < 0.001). Boxes represent upper and lower quartiles, the line represents the median, and the X represents the mean. dlPFC, dorsolateral prefrontal cortex; dmPFC, dorsomedial prefrontal cortex.

Article Snippet: The funding sources and the manufacturer of exenatide once weekly (Bydureon, AstraZeneca) had no influence on the trial design or data analysis.

Techniques: Control

Journal: JCI Insight

Article Title: Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial

doi: 10.1172/jci.insight.159863

Figure Lengend Snippet: ( A ) Baseline DAT availability in striatum, caudate, and putamen in AUD patients did not differ from that in healthy controls. Data were analyzed with a 1-way ANCOVA, adjusted for baseline DAT availability. Healthy controls, n = 21; patients at baseline, n = 45. ( B ) At the week 26 rescan, DAT availability in striatum, caudate, and putamen was significantly lower in the exenatide group compared with the placebo group [striatum, F (1,13) = 4.978, P = 0.044; caudate, F (1,13) = 8.066, P = 0.014; putamen, F (1,13) = 6.571, P = 0.024]. Data were analyzed with an ANCOVA adjusted for age. Placebo, n = 9; exenatide, n = 7. * P < 0.05. ( A and B ) Boxes represent upper and lower quartiles, the line represents the median, and the X represents the mean.

Article Snippet: The funding sources and the manufacturer of exenatide once weekly (Bydureon, AstraZeneca) had no influence on the trial design or data analysis.

Techniques: